(NASDAQ: MRNA) Moderna's forecast annual revenue growth rate of -0.26% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.02%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.67%.
Moderna's revenue in 2025 is $2,232,000,000.On average, 26 Wall Street analysts forecast MRNA's revenue for 2025 to be $756,355,535,232, with the lowest MRNA revenue forecast at $663,373,811,376, and the highest MRNA revenue forecast at $882,154,338,096. On average, 26 Wall Street analysts forecast MRNA's revenue for 2026 to be $762,215,727,912, with the lowest MRNA revenue forecast at $521,166,469,008, and the highest MRNA revenue forecast at $960,290,240,496.
In 2027, MRNA is forecast to generate $888,014,530,776 in revenue, with the lowest revenue forecast at $430,919,501,736 and the highest revenue forecast at $1,266,973,657,416.